Probiodrug CEO outlines Phase IIb plans for potential Alzheimer’s treatments

On the back of biomarker data that indicates that its approach to targeting pyroglutamate-Abeta is a promising therapeutic strategy to fight Alzheimer’s disease, Probiodrug is now ramping up plans to run Phase IIb trials in the US and the EU. Speaking at the 2018 Biotech Showcase, Probiodrug co-founder and CEO Konrad Glund explained to Scrip the implications of previous results with its small molecule and monoclonal antibody approaches and described the company’s strategy for moving the programs forward.